• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    6/8/23 1:32:10 PM ET
    $ACRX
    $COEP
    $CVRX
    $ELOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACRX alert in real time by email

    Gainers

    • ThermoGenesis Holdings (NASDAQ:THMO) shares moved upwards by 21.1% to $1.49 during Thursday's regular session. Trading volume for this security as of 13:30 EST is 476.6K, which is 38.5% of its average full-day volume over the last 100 days. The company's market cap stands at $2.8 million.
    • GT Biopharma (NASDAQ:GTBP) shares moved upwards by 20.54% to $0.39. The current volume of 575.8K shares is 237.4% of GT Biopharma's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $14.4 million.
    • AcelRx Pharmaceuticals (NASDAQ:ACRX) shares increased by 17.42% to $1.28. AcelRx Pharmaceuticals's stock is trading at a volume of 221.5K shares as of 13:30 EST. This is 103.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.9 million.
    • CVRx (NASDAQ:CVRX) stock rose 15.17% to $14.72. The current volume of 293.2K shares is 221.5% of CVRx's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $304.8 million.
    • Navidea Biopharmaceutical (AMEX:NAVB) stock rose 14.87% to $0.09. The current volume of 3.1 million shares is 152.1% of Navidea Biopharmaceutical's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $3.2 million.
    • LENSAR (NASDAQ:LNSR) stock moved upwards by 14.75% to $3.81. LENSAR's stock is trading at a volume of 93.1K shares as of 13:30 EST. This is 390.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $42.3 million.

    Losers

    • Precipio (NASDAQ:PRPO) stock decreased by 27.5% to $0.49 during Thursday's regular session. As of 13:30 EST, Precipio's stock is trading at a volume of 854.5K, which is 1523.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $11.5 million.
    • First Wave BioPharma (NASDAQ:FWBI) shares declined by 17.47% to $1.37. Trading volume for this security as of 13:30 EST is 137.5K, which is 154.2% of its average full-day volume over the last 100 days. The company's market cap stands at $2.6 million.
    • Kezar Life Sciences (NASDAQ:KZR) shares declined by 14.15% to $2.5. The current volume of 552.6K shares is 53.1% of Kezar Life Sciences's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $180.9 million.
    • Eloxx Pharmaceuticals (NASDAQ:ELOX) stock declined by 12.95% to $6.12. Trading volume for this security as of 13:30 EST is 53.5K, which is 11.3% of its average full-day volume over the last 100 days. The company's market cap stands at $13.2 million.
    • Coeptis Therapeutics (NASDAQ:COEP) shares fell 12.47% to $1.61. As of 13:30 EST, Coeptis Therapeutics's stock is trading at a volume of 891.3K, which is 222.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $34.6 million.
    • PolarityTE (NASDAQ:PTE) shares declined by 12.43% to $0.25. Trading volume for this security as of 13:30 EST is 467.4K, which is 435.3% of its average full-day volume over the last 100 days. The company's market cap stands at $1.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRX
    $COEP
    $CVRX
    $ELOX

    CompanyDatePrice TargetRatingAnalyst
    Kezar Life Sciences Inc.
    $KZR
    10/17/2025$7.00Buy → Hold
    Jefferies
    Kezar Life Sciences Inc.
    $KZR
    10/17/2025Outperform → Mkt Perform
    William Blair
    CVRx Inc.
    $CVRX
    5/9/2025$7.00Neutral → Underweight
    Analyst
    CVRx Inc.
    $CVRX
    1/14/2025Mkt Perform → Outperform
    William Blair
    GT Biopharma Inc.
    $GTBP
    12/2/2024$11.00Buy
    ROTH MKM
    CVRx Inc.
    $CVRX
    9/10/2024$14.00Overweight
    Cantor Fitzgerald
    CVRx Inc.
    $CVRX
    7/11/2024$18.00 → $12.00Buy
    Lake Street
    CVRx Inc.
    $CVRX
    5/1/2024$30.00 → $23.00Buy
    Craig Hallum
    More analyst ratings

    $ACRX
    $COEP
    $CVRX
    $ELOX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jain Mudit K. bought $297,592 worth of shares (46,800 units at $6.36) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/23/26 6:00:12 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Jain Mudit K. bought $2,785 worth of shares (600 units at $4.64), increasing direct ownership by 12% to 5,650 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/18/26 5:22:25 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $468 worth of shares (20 units at $23.40), increasing direct ownership by 2% to 1,015 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:22:27 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ACRX
    $COEP
    $CVRX
    $ELOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kezar Life Sciences downgraded by Jefferies with a new price target

    Jefferies downgraded Kezar Life Sciences from Buy to Hold and set a new price target of $7.00

    10/17/25 8:25:43 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences downgraded by William Blair

    William Blair downgraded Kezar Life Sciences from Outperform to Mkt Perform

    10/17/25 8:25:32 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CVRx, Inc. downgraded by Analyst with a new price target

    Analyst downgraded CVRx, Inc. from Neutral to Underweight and set a new price target of $7.00

    5/9/25 8:41:10 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $ACRX
    $COEP
    $CVRX
    $ELOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting

    MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations reviewing the science and outcomes of Barostim therapy at the Technology and Heart Failure Therapeutics 2026 (THT) meeting. THT, the annual conference organized by the Cardiovascular Research Foundation® (CRF®), will be held March 2-4, 2026, in Boston, Massachusetts. The presentations include late-breaking clinical data, oral sessions and posters highlighting real-world outcomes, cardiac energetics, h

    3/2/26 8:30:00 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    GT Biopharma Reports Full Year 2025 Financial Results

    Phase 1 trial evaluating GTB-3650 TriKE® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 remains on track to initiate mid-2026 Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026 SAN FRANCISCO, CALIFORNIA, March 02, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural ki

    3/2/26 7:00:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LENSAR® Provides Update on Pending Acquisition by Alcon

    ORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today provided an update on the status of its pending acquisition by Alcon Research, LLC ("Alcon"). The Company and Alcon continue to cooperate with the U.S. Federal Trade Commission (the "FTC") staff in connection with its Request for Additional Information and Documentary Material (the "Second Request") and related review of the proposed acquisition of the Company by Alcon (the "Alcon Transaction"). In light of this continued review process, the Company currently expects to

    2/25/26 5:00:00 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $ACRX
    $COEP
    $CVRX
    $ELOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF HUMAN RESOURCES OFFICER Morrison Gregory was granted 34,000 shares (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    3/4/26 4:34:46 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Morrison Gregory

    3 - CVRx, Inc. (0001235912) (Issuer)

    3/4/26 4:33:52 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    PRES & CEO Hykes Kevin sold $61,349 worth of shares (7,763 units at $7.90) and was granted 159,000 shares, increasing direct ownership by 114% to 284,237 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    3/3/26 6:03:38 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $ACRX
    $COEP
    $CVRX
    $ELOX
    SEC Filings

    View All

    CVRx Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - CVRx, Inc. (0001235912) (Filer)

    3/3/26 5:15:34 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by GT Biopharma Inc.

    10-K - GT Biopharma, Inc. (0000109657) (Filer)

    3/2/26 7:05:57 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GT Biopharma Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits

    8-K - GT Biopharma, Inc. (0000109657) (Filer)

    3/2/26 7:05:27 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $COEP
    $CVRX
    $ELOX
    Leadership Updates

    Live Leadership Updates

    View All

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    GT Biopharma Appoints New Member to its Board of Directors

    SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors. "We are very pleased to welcome David to the Board of Directors. David is an experienced senior executive with global connections and a proven track record of success in working with corporate management teams," said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. "His guidance and perspective will be

    6/13/25 9:00:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $COEP
    $CVRX
    $ELOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LENSAR Inc.

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    11/14/24 4:05:15 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Coeptis Therapeutics Holdings Inc.

    SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    11/14/24 3:59:49 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by CVRx Inc.

    SC 13D/A - CVRx, Inc. (0001235912) (Subject)

    11/7/24 9:10:51 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $ACRX
    $COEP
    $CVRX
    $ELOX
    Financials

    Live finance-specific insights

    View All

    Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year

    NEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025. Below are some of the key financial performance metrics for the Company. Revenue Growth – Precipio's revenues increased from $18.5M in 2024 to $24.0M in 2025, an increase of 30% year over year. Q4-2025 revenues were $6.7M, an increase of 23% YoY from $5.4M in Q4-2024. Positive Adjusted EBITDA – Precipio will report Adjusted EBITDA of $0.95M for Q4-2025, and $1.23M for the full year 2025. This is compared to Adjusted EBITDA of $0.40M in Q4-2024 and ($1.5M) in full year 2024. Please

    2/25/26 9:30:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2025. Recent Highlights Total revenue for the fourth quarter 2025 was $16.0 million, an increase of 4% over the prior year quarterU.S. revenue for the fourth quarter of 2025 was $14.9 million, an increase of 4% over the prior year quarterTotal revenue for 2025 was $56.7 million, an increase of 10% over the prior yearActive implanting centers

    2/12/26 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026

    MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2025 financial and operating results after market close on Thursday, Feb. 12, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone

    1/29/26 4:10:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care